Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Stock Price

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, and sells in vitro diagnostic reagents and instruments, and vaccines in China and internationally. It operates through Diagnostics Division and Vaccine Division segments. The company offers chemiluminescence detection, biochemical, hepatitis B core antibody detection, and HIV reagents; rapid urine tests for hepatitis E antigen; chronic disease management, hepatitis E screening and prevention, women’s full life-cycle health management, smart laboratories, medical laboratory quality and competence accreditation, lean management consulting, blood safety testing, and internal quality control solutions; enzyme-linked immunosorbent assay, colloidal gold, nucleic acid, clinical test quality control products, and raw materials; and nucleic acid testing devices. It also provides HPV, hepatitis E, and nasal spray COVID-19 vaccines. In addition, the company offers bio-immune and immunoassay instruments, as well as automated production lines. Further, it provides bio-immune assays, including hepatitis virus, P85-Ab, TB-IGRA, and biochemical gastric tests; biochemical assays comprising helicobacter pylori antibodies, gastrin 17, and soluble transferrin receptors; and support services, such as after-sales and training center services. Additionally, the company engages in technology business incubation and development activities. The company was founded in 1991 and is headquartered in Beijing, China. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a subsidiary of Yangshengtang Co., Ltd.